Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting
1 other identifier
observational
200
1 country
5
Brief Summary
This is a retrospective medical record abstraction to evaluate the patterns of care for Gastrointestinal stromal tumors (GIST) in the community setting. Patient demographics and characteristics along with the treatments received will be described. Investigators will establish the percentage of patients who undergo surgery, the percentage of patients who are treated with kinase inhibitors as well as in what setting (adjuvant or metastatic) as well as the duration of therapy. Physician information will also be collected to assess for differences in treatment based on physician or geographical differences.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2008
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2009
CompletedFirst Submitted
Initial submission to the registry
April 3, 2009
CompletedFirst Posted
Study publicly available on registry
April 7, 2009
CompletedAugust 4, 2010
August 1, 2010
1 year
April 3, 2009
August 3, 2010
Conditions
Keywords
Eligibility Criteria
Patients diagnosed with GIST based on ICD-9 code from January 2005 to present will be eligible. This will include current active patients as well as patients who have expired and have medical chart available. Estimate reviewing approximately 300 charts total.
You may qualify if:
- Patients diagnosed with GIST based on ICD-9 code from January 2005 to present will be eligible. This will include current active patients as well as patients who have expired and have medical chart available.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- SCRI Development Innovations, LLClead
- Pfizercollaborator
Study Sites (5)
Florida Cancer Specialists
Fort Myers, Florida, 33901, United States
Georgia Cancer Specialists
Atlanta, Georgia, 30341, United States
Chattanooga Oncology Hematology Associates
Chattanooga, Tennessee, 37404, United States
Tennessee Oncology, PLLC
Nashville, Tennessee, 37023, United States
Virginia Cancer Institute
Richmond, Virginia, 23235, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Jeffrey F Patton, M.D.
SCRI Development Innovations, LLC
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
April 3, 2009
First Posted
April 7, 2009
Study Start
January 1, 2008
Primary Completion
January 1, 2009
Study Completion
February 1, 2009
Last Updated
August 4, 2010
Record last verified: 2010-08